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H
omeostatic regulation plays a criti-
cal role in human health and under-
lies diverse biological processes, in-
cluding hormone release,1 ionic balance,2,3
and cell-mediated immunity.4,5 In particular,
living systems employ negative feedback
circuits to maintain processes within phy-
siologic limits, preventing unrestricted am-
pliﬁcation cascades or positive feedback
cycles.68 A key homeostatically regulated
processwith signiﬁcantmedical relevance is
blood coagulation, the protease-driven po-
sitive-feedback cascade by which clots are
formed to stop blood loss from injured
vessels. Dysregulation of this process,
whether pathological or drug-induced,
leads to adverse outcomes: insuﬃcient co-
agulation promotes life-threatening hemor-
rhage, while uncontrolled coagulation
drives thrombosis;or intravascular clotting;
the potentially fatal medical condition under-
lying pulmonary embolism, stroke, and organ
infarction.9 Clinical prevention of thrombosis
revolves around the administration of anti-
coagulants, the levels of whichmust be tightly
controlled within a narrow therapeutic win-
dow to prevent coagulation and limit life-
threatening bleeds that are their primary side
eﬀect.10 Consequently, anticoagulants require
strict dose titration and monitoring,11,12 and
there remains a pressing need for safe, yet
eﬀective agents to improve the treatment of
thrombosis.
The advent of nanotechnology has en-
abled a plethora of engineering approaches
for improving the eﬃcacy and safety pro-
ﬁles of drugs.13,14 A number of these nano-
scale drug delivery schemes have drawn
inspiration from the ability of biological
systems in nature to coordinate multiple
molecular components to produce emer-
gent behaviors, in order to design nanosys-
tems that communicate across multiple
length scales, form positive feedback loops,
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ABSTRACT Antithrombotic therapy is a critical portion of the treatment regime for a number of life-
threatening conditions, including cardiovascular disease, stroke, and cancer; yet, proper clinical management of
anticoagulation remains a challenge because existing agents increase the propensity for bleeding in patients. Here,
we describe the development of a bioresponsive peptidepolysaccharide nanocomplex that utilizes a negative
feedback mechanism to self-titrate the release of anticoagulant in response to varying levels of coagulation activity.
This nanoscale self-titrating activatable therapeutic, or nanoSTAT, consists of a cationic thrombin-cleavable peptide
and heparin, an anionic polysaccharide and widely used clinical anticoagulant. Under nonthrombotic conditions,
nanoSTATs circulate inactively, neither releasing anticoagulant nor signiﬁcantly prolonging bleeding time.
However, in response to life-threatening pulmonary embolism, nanoSTATs locally release their drug payload
and prevent thrombosis. This autonomous negative feedback regulator may improve antithrombotic therapy by increasing the therapeutic window and
decreasing the bleeding risk of anticoagulants.
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and drive accumulation of drugs at disease sites.1517
Here, inspired by the human body's capacity to pre-
cisely orchestrate and control biological reaction net-
works, we sought to engineer nanoagents that could
autonomously regulate coagulation by self-titrating
the release of a systemically administered antico-
agulant, thereby improving its safety proﬁle. Existing
delivery strategies for anticoagulants have explored
the use of biodegradable polymers for controlled
release,1820 multivalent presentation to increase
potency,21,22 or reformulated drugs to enable alterna-
tive routes of administration.23 While anticoagulants
have previously been packaged in nanoparticle form,
these open-loop systems deliver their cargo without
any form of feedback regulation and cannot autono-
mously titrate the release of drugs in response to
dynamic circulatory conditions within the body.
In this study, we reformulate unfractionated heparin
(UFH), the prototypical clinical anticoagulant,24 into
a self-assembled nanocomplex that is responsive to
thrombin, a key protease of the coagulation cascade,
by leveraging the charge interaction of PEGylated
cationic peptides composed of thrombin-cleavable
substrates (Figure 1A) with naturally anionic heparin
(Figure 1B). The resultant complexes release heparin in
response to thrombin activity, which then interacts
with endogenous antithrombin (ATIII) to inhibit throm-
bin, the initial trigger of drug release, thereby creating
a negative feedback control circuit (Figure 1C). This
thrombin-activated release mechanism deploys more
anticoagulant during thrombosis, when the generation
of thrombin outpaces endogenous regulatory check-
points, compared to healthy coagulation, which is
normally tightly regulated. We explore the composi-
tion of PEGylated nanocomplexes and characterize
their in vitro and in vivo release of heparin, eﬃcacy in
a pulmonary embolism model of thrombosis, and
impact on systemic bleeding time. This nanoscale
self-titrating activatable therapeutic (nanoSTAT) has
the potential to prevent thrombosis with fewer bleed-
ing side eﬀects than its free counterpart.
RESULTS
Synthesis and Characterization of NanoSTATs. Unfrac-
tioned heparin is a mainstay drug used in the hospital
setting; yet, it is particularly difficult to dose due to its
unpredictable pharmacokinetics. Thus, its use requires
clotting time measurements and dose readjustment
every 34 h to maintain drug levels within the ther-
apeutic range.2527 Because it is highly anionic, hepar-
in is readily sequestered by cationic peptides,28,29 such
as its clinical antidote protamine, which is character-
ized by a very high net positive charge.30 There-
fore, we designed a cationic peptide sequence with
multiple arginine/lysine-rich regions separated by
thrombin-cleavable substrates (LVPR.RK4 sequence =
rkrk-(LVPRG-rkrk)3, lower case = D-isomer) that is cap-
able of inhibiting heparin activity while intact, yet
releases active heparin following degradation by
thrombin.31 D-Amino acids were used for the nonsub-
strate regions of the peptide in an effort to minimize
nonspecific proteolytic degradation. To further stabi-
lize the nanocomplexes in ionic solutions, prevent
nonspecific protein interactions, prolong circulation
time, and improve biodistribution, we conjugated the
FDA-approved polymer poly(ethylene glycol) (PEG,
5 kDa) to a subset of the lysine residues using amine-
reactive ester chemistry (Figure 1A).32,33 When the
heparin (∼18 kDa average MW) and PEG-LVPR.RK4 con-
jugate were mixed together, they self-assembled into
spherical nanoscale complexes, or nanoSTATs, as con-
firmed by transmission electron microscopy (Figure 2A).
Figure 1. Schematic of self-titrating activatable therapeutic. (a) PEGylation of peptides used to form nanoSTATs. (b) Self-
assembly of cationic PEG-peptide and anionic heparin to form nanoSTATs. (c) Negative feedback system for self-titrating
release of heparin in response to thrombin activity.
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To explore the impact of component ratios on
complex formation, we tested PEG:LVPR.RK4 reaction
ratios between 0:1 and 5:1 (mol/mol) and LVPR.RK4:
heparin mixing ratios of either 5:1 or 10:1 (mol/mol).
For each particle composition, we measured the re-
sultant nanoSTAT particle size and zeta potential in
phosphate-buﬀered saline (PBS) or 10% exosome-free
fetal bovine serum via dynamic light scattering (DLS).
In both solutions, increasing the LVPR.RK4:heparin
mixing ratio from 5:1 to 10:1 caused the nanoSTAT
hydrodynamic diameter to increase in size from the
nano- (∼150 nm) to the microscale (∼23 μm), while
increasing the PEG:LVPR.RK4 reaction ratio decreased
the complex size (Figure 2B). The zeta potential of
nanoSTATs was generally negative, particularly in 10%
serum, with the addition of PEG bringing the charge
closer to neutrality (Figure 2C). A component ratio of
25:5:1 PEG:LVPR.RK4:heparin generated the smallest
particles (hydrodynamic diameter ∼50 nm) and was
used for the remainder of in vitro and in vivo experi-
mentation. Finally, since some charged nanomaterials
are known to produce cytotoxic proﬁles,34,35 we
incubated human endothelial cells (HUVECs) with
nanoSTATs at representative therapeutic heparin
concentrations and established that no toxicity was
observed up to 10 U/mL, which corresponds to a
∼1000 U/kg heparin dose in the bloodstream, or an
order of magnitude higher than standard dosing regi-
mens (Figure S1).36 Furthermore, to conﬁrm the safety
proﬁle of nanoSTATs in vivo, we performed blood
smear analyses and hematoxylin and eosin staining
of organs at time points 1, 4, and 24 h following
the intravenous administration of 25:5:1 nanoSTATs
(200 U/kg heparin) in mice, the dose used hereafter in
our therapeutic studies. The peripheral blood smears
did not demonstrate any changes in blood cell mor-
phology or the leukocyte diﬀerential compared to free
heparin-treated or untreated controls (Figure S2), and
the H&E section did not show signs of inﬂammation,
tissue damage, or cell death (Figure S3).
Veiling and Unveiling of NanoSTATs in Vitro. Next, we
assayedwhether nanoSTATs could regulate the release
of heparin in response to clotting activity. We exploited
the serine protease thrombin as the drug release
trigger on the basis of its critical role in catalyzing the
formation of fibrin clots and regulating hemostasis
through positive and negative feedback circuits and
its sensitivity to inhibition by heparin.37 To characterize
Figure 2. In vitro characterization of nanoSTATS. (a) Transmission electron microscopy image of negatively stained
nanoSTATs with a 25:5:1 PEG:LVPR.RK4:heparin molar ratio (scale bar = 100 nm). (b) Mean hydrodynamic diameter of
nanoSTATs at varying PEG:LVPR.RK4:heparin ratios in PBS and 10% serum (n = 3 per condition, SD). (c) Zeta potential of
nanoSTATs at varying PEG:LVPR.RK4:heparin ratios in PBS and 10% serum (n = 3 per condition, SD). (d) Heparin activity when
complexed with peptides and incubated with thrombin, as determined by anti-FXa assay (n = 3 per condition, SD). Pep,
peptide; D, D-isomer; Thr, thrombin. (e) Release proﬁle of heparin from nanoSTATs as a function of thrombin concentration
and incubation time. Amount of heparin released was determined by anti-FXa assay (n = 3 per condition, SD).
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thrombin-triggered disassembly, we incubated nano-
STATs with or without thrombin (500 nM) at 37 C and
assayed the samples by analytical FPLC. The control
sample chromatogram exhibited a sharp peak at
∼7 mL corresponding to intact nanoSTATs, which
was absent in the presence of thrombin and instead
replaced by a broad peak from ∼11 to 17 mL, corre-
sponding to the profile of free heparin (Figure S4); free
heparin was therefore below the limit of detection in
the sample of intact nanoSTATs and released upon
incubation with thrombin. To confirm the essentially
complete incorporation of free heparin into nano-
STATs, we performed an electrophoretic gel retarda-
tion assay followed by Alcian Blue staining for heparin,
showing that the free heparin band is absent from the
nanoSTAT sample lane (Figure S5). To determine the
accessibility of heparin when complexed, we mixed
nanoSTATs with Azure II, a metachromatic dye that
exhibits a shift in absorbance upon electrostatic inter-
action with heparin. We observed that intact nano-
STATs exhibited little interaction with Azure II, while
nanoSTATs incubated with thrombin (500 nM) caused
a significant increase in absorbance at 530 nm (Figure
S6).23 Taken together, these data demonstrate that
heparin is shielded from external charge interactions
when complexed and that thrombin cleavage of
the PEG-LVPR.RK4 causes the dissociation of the
charge-based nanoSTATs and results in the release
of heparin.
To investigate whether the complexation of hepa-
rin modulates its anticlotting activity, we performed an
anti-Factor Xa (FXa) assay on samples of intact and
thrombin-cleaved nanoSTATs. This assay measures
heparin activity based on its capacity to inhibit the
enzymatic activity of FXa, one of several serine pro-
tease targets of heparin, using a chromogenic sub-
strate. Intact heparin-containing nanoSTATs reduced
heparin activity by∼80% relative to free heparin, while
heparin activity was fully restored when nanoSTATs
were incubated with thrombin (Figure 2D). In light of
the evidence that free heparin is nearly completely
encapsulated by nanoSTAT particles (Figures S4
and S5), the residual ∼20% heparin activity observed
in intact nanoSTATs suggests that not all bound hepar-
in was rendered biologically inactive, though it is
possible that trace amounts of noncomplexed heparin
may contribute to the residual activity. Heparin activity
did not diﬀer between preformed complexes incu-
bated with thrombin and free heparin mixed with
peptides that had been previously cleaved by throm-
bin, conﬁrming that peptide cleavage sites remain
accessible while embedded in nanoSTATs and that
cleaved LVPR.RK4 fragments are unable to inhibit
anticoagulant activity. Furthermore, incubation of nano-
STATs formedwith D-stereoisomers of LVPR.RK4 (which
confers resistance against protease cleavage) with
thrombin led to minimal unveiling of heparin activity,
supporting the interpretation that thrombin cleavage
of LVPRG sites is responsible for the functional unveil-
ing of heparin. These experiments show that our
peptideheparin nanoSTATs veil heparin activity
when intact but release fully functional heparin in
response to thrombin cleavage.
Coagulation is a dynamic process where as little as
∼1030 nM of activated thrombin is needed to form a
ﬁbrin clot and up to 3001000 nM of total thrombin
can be generated within minutes.38 To investigate
the kinetics of heparin release under physiologically
relevant conditions, we incubated nanoSTATs with
diﬀerent concentrations of thrombin (11000 nM)
and monitored heparin release following deﬁned
periods (2, 5, and 10 min) by the anti-FXa assay. As
anticipated, the observed elevation in heparin re-
lease followed the track of increasing thrombin con-
centration, reaching a plateau of nearly complete
release (>95%) in response to 180 nM thrombin for
all incubation times tested (Figure 2E). Similarly,
heparin release increased over time in response to
thrombin exposure across the range of concentra-
tions tested. These data indicate that heparin release
is a function of thrombin activity and time at physio-
logically relevant concentrations and time scales,
behavior that reﬂects the self-titrating properties of
nanoSTATs.
NanoSTATs Exhibit Responsive Behavior ex Vivo. To test the
effect of nanoSTATs on plasma, we first performed an
activated partial thromboplastin time (aPTT) clotting
assay, which is used clinically to monitor heparin levels
in patients by measuring the time it takes a plasma
sample to clot when coagulation is triggered by an
activator such as silica or ellagic acid. Current clinical
guidelines for heparin treatment recommend dose
ranges that yield aPTTs ∼1.52.3-fold above the con-
trol bleeding time, which yields a relatively narrow
therapeutic window that is further complicated by the
need for each laboratory to internally standardize and
validate their own reference ranges.12,36 In human
plasma samples spiked with free heparin, the clotting
time increased dramatically in a dose-dependent man-
ner from∼29 s in the absence of heparin (0 U/mL) up to
∼44 s (∼1.5-fold over control) with exposure to only
0.8 U/mL and as long as ∼136 s (∼5-fold over control)
for 2.0 U/mL (Figure 3A). In contrast, plasma samples
spiked with identical doses of heparin nanoSTATs
exhibited significantly shorter increases in clotting
time, reaching 46 s (∼1.5-fold over control) at a dose
of only 2 U/mL (p < 0.001 by Student's t-test, n = 34
per condition). Our results indicate that, relative to the
free form, an equivalent dose of heparin sequestered
within nanoSTATs leads to a significantly shorter aPTT,
which is clinically associated with lower risk of
bleeding39,40 and suggests that nanoSTATs may offer
a wider therapeutic window than traditional UFH
treatment.
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To further analyze the anticoagulant mechanism of
the nanoSTATs, we performed real-time thrombin
generation assays in human plasma. The thrombin
generation curves of free heparin and nanoSTATs
exhibited distinct patterns (Figure 3B,C, Figure S7).
The time to initial thrombin formation (lag time), which
correlates with clot initation, was prolonged in a
dose-dependent manner by free heparin as expected.
In contrast, the lag time of plasma samples with
identical doses of nanoSTATs did not changemarkedly
as the eﬀective concentration of heparin increased
(Figure 3D, p < 0.01 by Student's t-test, n = 3 per
condition).41,42 These results were consistent with the
aPTT assay and support the model that nanoSTATs
initially veil complexed heparin and block its activity.
Following the onset of clotting, nanoSTATs demon-
strated anticoagulant activity similarly to free heparin
by reducing the maximum (peak) and total (endo-
genous thrombin potential, ETP) thrombin generation
relative to the untreated control (0 U/mL), suggesting
that the nanoSTATs release active heparin during the
clotting process. However, the magnitude of the re-
ductions in peak thrombin and ETP was signiﬁcantly
smaller for nanoSTATs at equivalent heparin concen-
trations greater than 0.2 U/mL (p < 0.001 by Student's
t-test, n = 3 per condition; Figure 3E,F). This trend was
particularly apparent in the peak thrombin activity,
which shows that the generation of activated thrombin
is needed to ﬁrst release heparin from the nanoSTATs
in order to block further coagulation, as opposed to
free heparin, which is active from the outset. The ETP of
nanoSTATs never decreased below 40%of the baseline
level even at the highest dose tested (1.6 U/mL), which
was over twice the maximum recommended dose of
UFH,12,25,36 whereas the equivalent concentration of
free heparin reduced the ETP by ∼80%. This observa-
tion suggests that nanoSTATsmaybuﬀer against safety
risks from dose escalation, as studies have shown that
reductions in ETP greater than 80% relative to normal
baseline have been correlated with risk of bleeding in
patients.43,44
NanoSTATs Remain Veiled in the Absence of Thrombosis and
Do Not Increase Bleeding. In the bloodstream, nanoSTATs
must navigate a complexmilieu of proteins and plasma
components without experiencing premature release
of their cargo until exposed to sites of thrombus
formation. To validate whether anticoagulant activity
of nanoSTATs remains suppressed in vivo under
healthy conditions, we performed two sets of cir-
culation time experiments. First, using fluorescently
labeled heparin, we sampled the blood of mice in-
jectedwith either nanoSTATs or free heparin (100U/kg,
n = 3 mice) and measured the plasma fluorescence
over time (Figure 4A). These results indicated that
nanoSTATs exhibited a rapid initial clearance half-life
withinminutes, while a secondary half-life persisted for
greater than an hour, which was consistent with the
clearance behavior of other heparin-functionalized
nanoparticles.45 Next, we injected mice with either
nanoSTATs or free heparin and tested the plasma for
Figure 3. Ex vivo characterization of nanoSTATs in humanplasma. (a) Activated partial thromboplastin time of normal human
control plasma spiked with free heparin or nanoSTATs (nS) (**p < 0.01; ***p < 0.001 by two-way ANOVAwith Bonferroni post
test; n = 3 per condition, SD). (b, c) Real-time thrombin generation in plasma in the absence or presence of increasing
concentrations of (b) free heparin (Hep) or (c) nanoSTATs (n = 3 per condition). (d) Lag time, (e) peak thrombin, and (f)
endogenous thrombin potential (ETP) calculated from the thrombin generation assays in (b) and (c) (*p < 0.05 by two-way
ANOVA with Bonferroni post test; n = 3 per condition, SD).
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heparin activity using the anti-FXa assay (Figure 4B).
This experiment showed that unlike the functional
activity of free heparin, which matched its fluores-
cence signal, nanoSTATs exhibited little to no heparin
activity at any of the measured time points. Together,
these studies showed that nanoSTATs veil heparin
function while in circulation, leading to reduced levels
of heparin activity in the blood pool relative to free
heparin.
The primary side eﬀect of clinical anticoagulants,
including heparin, is moderate to potentially fatal
bleeding.10,11 To assess whether nanoSTATs reduce
bleeding side eﬀects, we performed tail transections
on mice after they were treated intravenously with
nanoSTATs (200 U/kg), free heparin (200 U/kg), or PBS
(control) andmeasured the time elapsed until bleeding
ceased (Figure 4C). Free heparin increased the mean
bleeding time ofmice (∼9.2min) by greater than 280%
over that of control PBS-treated mice (∼3.3 min). By
contrast, the mean bleeding time of nanoSTAT-treated
mice (∼4.3 min) was signiﬁcantly shorter than that of
the heparin-treated group and only 30% longer than
the control bleeding time (p < 0.01 by one-way ANOVA
with Tukey post test, n = 57 mice). The reduction in
the bleeding time of mice administered with nano-
STATs versus free heparin suggests that the level of
thrombin activity in response to injury did not unveil
suﬃcient heparin to signiﬁcantly impact bleeding
cessation. This ﬁnding may be due to the fact that
sealing major wounds is largely dependent on platelet
activation and plug formation, a process that requires
considerably lower levels of activated thrombin than
during thrombus formation.46,47 Taken together, these
data showed that nanoSTATs circulate in an inactive
form, veiling heparin activity and decreasing the risk of
bleeding.
NanoSTATs Prevent Thrombosis in Vivo. To evaluate
the ability of nanoSTATs to prevent thrombosis
in vivo, we utilized a thromboplastin-induced model
of pulmonary thromboembolism, which we and others
have shown leads to deposition of microembolisms
primarily in the lungs (Figure S8).48,49 Mice were ad-
ministered fibrinogen labeled with near-infrared dyes
to monitor the formation of fibrin clots in the lungs by
fluorescent imaging after thromboplastin challenge
(2 μL/g b.w.). The lungs ofmice treatedwith nanoSTATs
(200 U/kg) showed a ∼75% reduction (p < 0.01, one-
way ANOVA with Tukey post test, n = 5 mice) in the
burden of clots compared to the lungs of control-
treated mice (Figure 5A,B). This reduction in the for-
mation of clots caused by nanoSTATs was statistically
equivalent to the therapeutic efficacy achieved by
the corresponding dosage of free heparin (200 U/kg,
Figure S9). Moreover, histological analysis showed that
microvessels in the lungs of control-treated animals
contain thrombi (arrows in Figure 5C, top right panel),
whereas such vessels in animals treated with either
free heparin or nanoSTATs were largely patent, as
evidenced by the presence of red blood cells (arrow
heads in Figure 5C). Combined with the data from
the tail bleeding assay, these observations suggest
that nanoSTATs prevent thrombosis as effectively as
free heparin but with a significantly reduced risk of
bleeding.
DISCUSSION
Anticoagulation is vital for the prophylaxis and
treatment of life-threatening thrombosis; however,
inhibiting the body's natural ability to form blood clots
predisposes patients to severe bleeding complications.
The ideal anticoagulant is a drug that prevents coagu-
lation without promoting bleeding.9,11 Here, we en-
gineered a nanocomplex that autonomously titrates
the release of anticoagulant in response to endogen-
ous levels of activated thrombin in thrombosis, creat-
ing a negative feedback circuit that regulates the
coagulation cascade with negligible increases to the
risk of bleeding. While Maitz et al. also recently
Figure 4. In vivo bleeding time of nanoSTATs. (a) Circulation time of nanoSTATs (nS) and free heparin as determined by
ﬂuorescence using FITC-heparin (n = 3mice, SE). (b) Circulation time of nanoSTATs (nS) and free heparin (Hep) as determined
by anti-FXa assay onmouse plasma samples withdrawn over time (n = 3mice, SE). (c) Tail bleeding time of mice administered
200 U/kg of free heparin or nanoSTATs (**p < 0.01 by one-way ANOVA with Tukey post test; n = 57 mice, SE).
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assessed the function of a self-regulating anticoag-
ulant material through ex vivo simulations, we tested
our nanoSTATs in vivo and demonstrated therapeutic
and safety characteristics that can only be investigated
in animal models. Furthermore, our nanoformulation is
designed for systemic thrombosis prevention in con-
trast to their hydrogel platform, which is better suited
for highly localized anticoagulation applications (e.g.,
surface coating of blood contacting medical devices).8
Engineering approaches have also been used to design
bioresponsive thrombolytics;antithrombotic therapies
designed to dissolve existing clots rather than prevent
their formation;including recombinant proteins
47,50
or polymeric microparticles51 activated by proteolytic
or biophysical triggers associated with thrombosis that
decrease bleeding and expand therapeutic windows.
Looking forward, several clinical applications warrant
further investigation with our nanoSTATs. Since the
model used heremimics the development of emboli in
the microvasculature, future testing will assess nano-
STATs' ability to treat thrombosis in larger vessels,
which are representative of clinical situations such as
myocardial infarction or thrombotic stroke.52,53 Further
studies are also needed to understand the impact of
the nanoSTAT formulation on other side eﬀects asso-
ciated with UFH, such as heparin-induced thrombocy-
topenia and platelet dysfunction.25,54,55
Numerous recent nanoscale drug delivery systems
utilize responsiveness to biological stimuli to control
drug biodistribution in vivo.56,57 A majority of these
systems operate without the ability to self-regulate;
such nanoparticles are adequate for site-directed de-
livery, but impractical for applications requiring adjus-
table functionality under varying biological conditions.
Only a small number of self-regulating nanocarriers
have been developed, with glucose-responsive insulin
delivery being the most well-known example.58,59 In
contrast to the glucoseinsulin feedback loop, which
functions over several hours through the body's down-
stream response to insulin to indirectly aﬀect the initial
glucose trigger,60 we have designed a direct negative
feedback loop that immediately modulates its proteo-
lytic trigger in conjunction with a single readily avail-
able eﬀector, an approach that is well suited for
regulating enzymatic cascades that operate on rapid
time scales. Our strategy was achieved through facile
noncovalent modiﬁcation of the clinically approved
anticoagulant UFH using biocompatible materials,
which may mitigate the translational risk of this na-
notherapeutic. A more detailed examination of the
nanoSTATs' impact on hemodynamic parameters and
immunological markers would help to verify the in vivo
safety of the system.30 The clearance kinetics of nano-
STATs suggest they may be well-suited for administra-
tion by continuous infusion in an in-patient setting,
where rapid cessation of anticoagulation is often
required in order to undertake further medical proce-
dures. For longer-term prophylactic applications,
strategies for extending the circulation time of the
nanoSTATs may be required, such as optimizing the
density and attachment sites of PEG, using longer chain
polymers, and varying the ratio of non-PEGylated to
PEGylated peptides. Other potential improvements
to our system include the use of alternative peptide
substrates that are sensitive to upstream coagulation
factors such as FXa,61 further functionalizing nano-
STATs with ﬁbrin-targeted ligands to concentrate
drugs in areas of clotting,17,62,63 and delivering direct
coagulation inhibitors instead of UFH.64 Furthermore,
this paradigm is readily extensible to the regulation
of additional disease-associated proteases via the
modular protease-sensitive and therapeutic-binding
domains, enabling the design of next-generation self-
titrating medicines.
CONCLUSION
In summary, this work represents, to the best of our
knowledge, the ﬁrst self-titrating anticoagulant nano-
formulation that decreases the risk of bleeding while
maintaining antithrombotic eﬃcacy. By incorporating
Figure 5. In vivo therapeutic eﬃcacy of nanoSTATs. (a) Quantiﬁcation of ﬁbrin deposited in the lungs of mice dosed with
thromboplastin (T, 2 μL/g body weight) and nanoSTATs (nS, 200 U/kg) or free heparin (Hep, 200 U/kg) (**p < 0.01 by one-way
ANOVA with Tukey post test; n = 5 mice, SE). (b) Near-infrared ﬂuorescent scans of excised lungs to assess VT750-labeled
ﬁbrinogen following intravenous injectionof PBS, T only, TþnS, andTþHep. (c) H&E stainingof lungs inmice under the same
conditions as in (b). Arrow denotes ﬁbrin clots; arrowheads denote patent vessels (scale bar = 100 μm).
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negative feedback control, nanoSTATs further expand
the repertoire of nanomedicines available for the
treatment of thrombosis and may lead to the devel-
opment of safer antithrombotics.
MATERIALS AND METHODS
Peptide Synthesis and Functionalization. Peptides (LVPR.RK4 =
rkrkLVPRGrkrkLVPRGrkrkLVPRGrkrk, lower case = D-isomer)
were synthesized by standard FMOC solid-phase peptide syn-
thesis (Koch Institute Biopolymers Core or Tufts University Core
Facility), lyophilized, and resuspended at 5 mg/mL in ddH2O.
Peptides were PEGylated through incubation of a 5 mg/mL
stock peptide solution with amine-reactive 5000 Da poly-
(ethylene glycol)-succinimidyl valerate (PEG-SVA, Laysan
Bio Inc.) for 1 h at room temperature.
Physical Characterization of NanoSTATs. NanoSTATs were gener-
ated with peptide and PEGmolar ratios as reported, with a fixed
heparin (sodium salt from porcine mucosa, Sigma, ∼18 000 Da
average MW) concentration of 20 U/mL (∼0.1 mg/mL) unless
reported otherwise. For measurements in ionic solutions,
10 PBS stock was added to preformed nanoSTAT solutions
for a final concentration of 1 PBS. For measurements in
serum, bovine serum (Gibco) was added to a concentration of
10% (v/v). Mean hydrodynamic diameter was determined via
dynamic light scattering of a 50 μL sample at 20 U/mL heparin
(ZetaSizer Nano Series, Malvern). Zeta potential was measured
via electrophoretic light scattering on a 900 μL particle sample
at 20 U/mL (ZetaSizer Nano Series). The morphology of nano-
STATs was visualized by dialyzing overnight against 1 PBS in
20 kDa MWCO dialysis cassettes (Thermo), negatively staining
samples with 2% uranyl acetate, and imaging via transmission
electronmicroscopy using an FEI Tecnai Spirit operated at 80 kV.
Veiling and Unveiling of Function in Vitro. The heparin activity
of intact nanoSTATs was determined using the anti-FXa
assay (Sekisui Diagnostics) according to manufacturer instruc-
tions. The release of heparin was determined by incubating
nanoSTATs with various concentrations of human thrombin
(Haematologic Technologies) at 37 C for the reported amounts
of time. The activity of the released heparin was then deter-
mined using the anti-FXa assay.
Cytotoxicity Assays. Human umbilical vein endothelial cells
(passage 9) were cultured in EGM-2 media (Lonza) on a 96-well
plate. When cells reached 70% confluency, nanoSTATs,
PEG-LVPR.RK4, free LVPR.RK4, or free heparin was added as a
9 stock in PBS, diluted in EGM-2. After 24 h elapsed, cell
viability was quantified by the MTS assay (CellTiter AQueous
One, Promega) based on OD490 after 1 h incubation.
Blood Smears. Swiss Webster mice were injected with nano-
STATs or free heparin at 200 U/kg body weight. Blood was
sampled at the specified time points by retro-orbital collection
with uncoated capillaries (Drummond), mixedwith 1 PBS with
10 mM EDTA, and spread onto glass slides using standard
preparation techniques. Dried blood smears (3 smears per time
point) were stained with Wright-Giemsa stain in methanol
(Sigma), rinsed sequentially in 1 PBS and distilled water, and
air-dried prior to imaging.
H&E Staining. Swiss Webster mice were injected with nano-
STATs at 200 U/kg body weight. Mice were sacrificed at the
specified time points, and the lungs, heart, spleen, liver, kidney,
and brain were isolated and fixed in 4% w/v paraformaldehyde
(in 1 PBS) overnight. Fixed organs were paraffin-embedded,
sectioned to 5 μm thickness, and H&E stained by the Koch
Institute Histology Core.
FPLC Analysis. NanoSTATs were formulated as described
above using fluorescently labeled (FITC) heparin (Polysciences).
A sample of nanoSTATswas incubatedwith thrombin (500 nM) at
37 C for 30 min. Analytical samples of nanoSTATs, nanoSTATs
incubated with thrombin, and free heparin were applied to a
Superdex 200 column pre-equilibriated with PBS. Absorbance of
the columneffluentwasmonitored at awavelengthof 488 nmby
a UV flow-through detector.
Alcian Blue Staining. The 25:5:1 PEG:LVPR.RK4:heparin nano-
STATs were formulated as described above at a heparin
concentration of 3 mg/mL. A 60 μg amount of free heparin or
60 μg of heparin contained in nanoSTATs was loaded into a 1%
agarose gel. The gel was run at 60 V in 1 TAE for 20 min, then
stained with 0.1% Alcian Blue 8GX (Sigma) in 2% v/v acetic acid.
The gel was destained overnight in 2% v/v acetic acid on an
orbital shaker prior to imaging on a uniform lightbox.
Azure II Assay. A sample of nanoSTATs was incubated with
thrombin at 37 C for 30min. NanoSTATs, nanoSTATs incubated
with thrombin (500 nM), and free heparin were thenmixedwith
0.1 mg/mL Azure II solution at a 1:10 volumetric ratio, and the
absorbance was read at 530 nm with a SpectraMAX Plus spec-
trophotometer (Molecular Devices).
aPTT Assay. Varying concentrations of nanoSTATs or free
heparin were added to 50 μL of control normal human plasma
(Thermo Scientific) and incubated with 50 μL of aPTT reagent
(Thermo Scientific) at 37 C for 3min. Then 50 μL of 25mMCaCl2
(Sigma) preincubated at 37 C was added to samples, and
clotting was monitored via absorbance at 605 nm with a
SpectraMAX Plus spectrophotometer (Molecular Devices).
Thrombin Generation Assay. Varying concentrations of nano-
STATs or free heparin were added to 20 μL of control normal
human plasma (Thermo Scientific). Real-time thrombin gen-
eration was measured using the Technothrombin TGA kit
(Technoclone) using the RD reagent according to manufacturer
instructions. The fluorescence was monitored using a TECAN
Infinite M200 Pro, and thrombin generation was calculated
using the corresponding Excel evaluation software provided
by Technoclone.
Circulation Times. Healthy female Swiss Webster mice (34
months, n = 3 mice per condition) were injected via tail vein
with either nanoSTATs or free heparin at 100 U/kg, formulated
with 1 PBS. For measurement of heparin fluorescence, blood
samples were collected through retro-orbital blood draw and
centrifuged at 2900g for 5 min to isolate plasma, which was
then analyzed by fluorimetry using a Spectramax Gemini EM
fluorescence microplate reader (Molecular Devices) at excita-
tion/emission wavelengths of 485/538 nm. For measurement of
anti-FXa activity, blood samples were collected in tubes con-
taining 3.2% sodium citrate (Sigma) for a final volume ratio of
9:1 (blood:citrate) through retro-orbital blood draws and cen-
trifuged at 2900g for 5 min to isolate the plasma. Heparin
activity in the plasma was then determined using the anti-FXa
assay.
Tail Bleeding Time Assay. Mice (n = 57 per condition) were
anesthetized with isoflurane gas and administered nanoSTATs
(200 U/kg), free heparin (200 U/kg), or PBS control. After 5 min,
2mmof distalmouse tail was removed by scalpel. Bleeding time
was determined by lightly dabbing the tail with Kimwipe tissues
(Kimtech) until bleeding fully ceased for at least 1 min.
Pulmonary Embolism Assay. Bovine fibrinogen (Sigma) was
reacted with near-infrared fluorochromes (Vivotag-750-NHS,
PerkinElmer) at a 2:1 fluorophore:protein molar ratio in PBS
for 1 h and purified by column centrifugation (100 kDa cutoff,
Millipore) to remove unreacted fluorophores. Ampules of
thromboplastin from rabbit brain (Sigma, #44213) were recon-
stituted with 2 mL of PBS each. Mice (n = 5 per condition) were
anesthetized with isofluorane gas and coadministered nano-
STATs (200 U/kg), free heparin (200 U/kg), or PBS control and
1 nmol of VT750-fibrinogen via tail vein injection. After 5 min,
mice were injected with thromboplastin (2 uL/g b.w.). After
30 min, mice were euthanized with CO2, and the lungs were
harvested and imaged on a LI-COR Odyssey infrared imaging
system. Fibrin deposition was then quantified using ImageJ
software. For histologic analysis, paraffin-embedded sections of
lungs were prepared (Koch Institute Histology Core). Lungs
were first fixed by incubating in 4% paraformaldehyde over-
night. Hematoxylin and eosin immunochemical staining of lung
sections was used to visualize clots in the lungs.
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Statistical Analyses. Student's t-test and ANOVA analyses were
calculated with GraphPad Prism 5.0.
All experimental protocols involving animals were ap-
proved by the MIT Committee on Animal Care (protocols
#0411-036-14 and 0414-022-17).
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